Arca
Skip to content
Tools
Tools

Hepatitis B virus

Drug research and approvals for hepatitis B virus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 146 studies of hepatitis B virus are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 146
  • Trials authorized in Canada: 26
  • FDA orphan approvals: 0
  • EU medicines: 6

Recruiting now

Newest posted first, of 146 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,674 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 397 whose ending is known, 59% met their primary endpoint, 6% missed it and 35% stopped early.

  • Completed, result not reported64639%
  • Status unknown38923%
  • Ongoing24214%
  • Met its primary endpoint23514%
  • Stopped: other or unclear754%
  • Stopped: sponsor or business decision292%
  • Missed its primary endpoint221%
  • Stopped: enrollment or feasibility221%
  • Stopped: lack of efficacy7<1%
  • Stopped: safety7<1%

Trials authorized in Canada

The 10 newest of 26; search them all in Canada trials
May 14, 2025A randomized, double-blind, active-controlled multicenter phase 2 study evaluating the efficacy and safety of ALG-000184 compared with tenofovir disoproxil…Pevifoscorvir sodium (ALG-000184) / Tenofovir disoproxilAligos TherapeuticsOngoing
Nov 6, 2024A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of…AB-101Arbutus BiopharmaClosed
Sep 23, 2024A phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with…Bepirovirsen (GSK3228836) / Daplusiran-tomligisiran (GSK5637608/JNJ-73763989)GSKOngoing
Jul 2, 2024A multicenter, randomized, double-blind, placebo- controlled study to assess the efficacy and safety of treatment with bepirovirsen in participants living with…Bepirovirsen (GSK3228836)GSKOngoing
Dec 16, 2022A phase 2 study to evaluate the safety, tolerability, and efficacy of regimens containing VIR-2218, VIR-3434, and/or peg-ifn in subjects with chronic hepatitis…Elebsiran (VIR-2218)/ Tobevibart (VIR-3434)/ Peginterferon ALFA-2AVir BiotechnologyOngoing
Nov 9, 2022Phase 3 multicenter, randomized, double-blind, study to assess the efficacy and safety of treatment with bepirovirsen in nucleos(t)ide analogue treated…Bepirovirsen (GSK3228836)GSKClosed
Nov 9, 2022Phase 3 multicenter, randomized, double blind, study to assess the efficacy and safety of treatment with bepirovirsen in hbeag negative nucleos(t)ide analogue…Bepirovirsen (GSK3228836)GSKClosed
Mar 30, 2022Randomised, open-label and parallel group trial to investigate the effects of oral bi 685509 alone or in combination with empagliflozin on portal hypertension…Bi 685509 / EmpagliflozinBoehringer Ingelheim (Canada) Ltd LteePending
Dec 21, 2020A phase 2b multi-centre, randomized, open-label study to assess the efficacy and safety of sequential treatment with GSK3228836 followed by pegylated…Bepirovirsen (GSK3228836)/ Peginterferon ALFA-2AGSKClosed
Jul 21, 2020An open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in patients with chronic hepatitis B via intrahepatic…Bepirovirsen (GSK3228836, isis 505358)GSKClosed

FDA orphan designations

Approved first, then open designations, newest first
Jul 15, 2003Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab…For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantationCubist PharmaceuticalsDesignated
Mar 8, 1995Hepatitis B immune globulin intravenous (human)Prophylaxis against hepatitis B virus reinfection in liver transplant patients.Biotest Pharmaceuticals CorporationDesignated

Medicines authorised in the EU

Newest first
Feb 18, 2021Heplisav BHepatitis B surface antigenDynavax GmbHEMA ↗
Sep 25, 2017Entecavir AccordEntecavir · genericAccord Healthcare S.L.U.EMA ↗
Sep 18, 2017Entecavir Viatris (previously Entecavir Mylan)Entecavir · genericViatris LimitedEMA ↗
Nov 30, 2009ZutectraHuman hepatitis B immunoglobulinBiotest Pharma GmbHEMA ↗
Jun 26, 2006BaracludeEntecavirBristol-Myers Squibb Pharma EEIGEMA ↗
Feb 2, 2005FendrixHepatitis B (rDNA) vaccine (adjuvanted, adsorbed)GlaxoSmithKline Biologicals S.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.